Loading
Adding the anti-VEGFR2 antibody ramucirumab to weekly paclitaxel lengthened survival by over two months in gastric cancer that had progressed after first-line chemotherapy, establishing the standard second-line regimen.
Phase 3 placebo-controlled trial of 665 patients with advanced gastric or junctional adenocarcinoma progressing after first-line platinum-fluoropyrimidine chemotherapy randomised to ramucirumab or placebo with weekly paclitaxel.
Median overall survival was 9.6 versus 7.4 months (hazard ratio 0.81), progression-free survival 4.4 versus 2.9 months and response 28 versus 16 percent; neutropenia, hypertension and fatigue were more frequent with ramucirumab.
Ramucirumab-paclitaxel is the second-line standard for HER2-negative gastric cancer after chemo-immunotherapy, and the comparator for newer agents.
Shares RAINBOW, Ramucirumab.
Shares Claudin 18.2-positive gastric cancer, PD-L1-high gastric cancer.
Shares Claudin 18.2-positive gastric cancer, PD-L1-high gastric cancer.
Shares Claudin 18.2-positive gastric cancer, PD-L1-high gastric cancer.
Shares Claudin 18.2-positive gastric cancer, PD-L1-high gastric cancer.